Chinese state-backed funds were yesterday active in selected stocks, people familiar with the matter said, seeking to cushion the blow from a sudden escalation in trade tensions with the US.
Among the funds’ targets were two large oil companies, the people said, asking not to be named discussing private information.
PetroChina Co (中石油), which fell as much as 3.5 percent in Shanghai, pared losses in afternoon trading to close with a 0.9 percent decline.
China Petroleum & Chemical Corp (中石化) also spiked briefly, though it ended the day down 4.2 percent. Industrial and Commercial Bank of China Ltd (中國工商銀行), the nation’s largest lender, displayed a similar pattern.
State funds stepped in after US President Donald Trump threatened China with steeper tariffs, ramping up tensions in a trade conflict that many investors had hoped was nearing an end.
While the large-cap stock moves helped major equity gauges close off their lows, the Shanghai Composite Index still finished down 5.6 percent, its steepest drop in three years.
Not all investors welcomed such moves.
“The government needs to come up with a basket of solutions to alleviate the market’s key concerns, rather than resorting to a short-term boost to stock prices, which would only prove to be futile and nothing more than a window-dressing act,” said Raymond Chen, a portfolio manager at Keywise Capital Management Beijing Ltd (凱思博投資管理).
Signs of government support also emerged outside the stock market.
At least one big Chinese bank offered to sell the US currency as the onshore yuan fell toward 6.80 per US dollar, according to traders, limiting depreciation in the Chinese currency after it dropped the most in nearly three months.
The China Securities Regulatory Commission did not immediately respond to a faxed request for comment.
While state funds helped ensure a steady bull market in Chinese stocks for much of 2016 and 2017, the government was widely criticized for its botched attempts to end a $5 trillion selloff in mid-2015.
This year, the Shanghai Composite is one of the world’s best-performing benchmark stock indexes. It is up 17 percent even after yesterday’s slide, buoyed by looser credit conditions in China and signs that Asia’s largest economy is stabilizing after a tough last year.
Just a few years ago, the millennial generation — generally defined as those born from the early 1980s through the mid-1990s — was synonymous with youthful rebellion. However, now, as the millennials ease into early middle age, they are finding their path out of their parents’ basement to be a lot harder than it was for earlier generations. The fundamental problem is that millennials are not building wealth. The wealth of the median US household headed by someone 35 or younger has actually shrunk in inflation-adjusted terms since the mid-2000s, even as the wealth of older Americans has continued to grow. An
Apple Inc’s decision to stop using Intel Corp processors in its Mac computers and switching to its own chips might benefit Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) and boost Taiwan’s high-tech exports, Australia and New Zealand Banking Group (ANZ) said in a note on Tuesday. The US tech giant announced the “Apple silicon” initiative at its annual Worldwide Developers’ Conference, which started on Monday. The company said the first Mac powered by its own chips would debut by the end of this year and all product lines might shift to the new architecture in the next two years. TSMC is likely to
Gogoro Inc (睿能創意) yesterday launched its first electric bicycle, the Gogoro Eeyo 1, in Taiwan, after unveiling the bike in New York in late May and in France on Tuesday. The company said it would also introduce the series in other European countries such as Germany and the Netherlands. The “Eeyo project” is the fourth of Gogoro’s eight projects that concentrate on smart transportation, which includes Gogoro’s electric scooter, battery swap system and electric scooter sharing service, company founder and chief executive officer Horace Luke (陸學森) told a media briefing in Taipei. “There are various types of city commuters. We will not
EXPERIMENTAL DRUG: While news about a COVID-19 vaccine is more eye-catching, developing a treatment would be more viable, the Senhwa boss said Senhwa Biosciences Inc (生華科) aims to raise NT$1.5 billion (US$50.57 million) by issuing 15 million new common shares in the third quarter of this year to fund the research of new drugs, including the experimental drug Silmitasertib for the treatment of COVID-19, the company said on Monday. That would be the firm’s largest fundraising effort after it raised more than NT$1.4 billion from an initial public offering on the Taipei Exchange (TPEX) in April 2017, chief financial officer Sarah Chang (張小萍) told the Taipei Times by telephone. The price of the new shares would depend on the firm’s average share price